Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Tranzyme Pharma Announces Completion Of Drug Discovery Collaboration With Bristol-Myers Squibb Co


Friday, 4 Jan 2013 05:10am EST 

Tranzyme Pharma announced the completion of chemistry-based drug discovery collaboration with Bristol-Myers Squibb. As a result of the joint research efforts, Tranzyme has transferred compounds to Bristol-Myers Squibb for further development across multiple drug targets. As part of this agreement, Tranzyme retains the option to further pursue select collaboration targets for internal development. The goal of the strategic collaboration, established in December 2009, was to deploy Tranzyme's chemistry technology, Macrocyclic Template Chemistry (MATCH), in the discovery of active macrocycles against a range of diverse biological targets that have historically been difficult to access with conventional small molecule chemistry. Under the terms of the agreement, Tranzyme had primary responsibility for early lead compound discovery. Bristol-Myers Squibb has primary responsibility for optimizing the identified lead compounds, and sole responsibility for completing preclinical and clinical development of all products arising from the collaboration, and for their commercialization globally. 

Company Quote

50.25
-0.52 -1.02%
27 Aug 2014